Finch Therapeutics
Finch Therapeutics, founded in 2014, specializes in microbiome therapeutics with a robust intellectual property estate and a portfolio of innovative assets targeting various therapeutic areas.
History of Finch Therapeutics
Finch Therapeutics was formed in 2014, aiming to leverage the genomic revolution and machine learning to spearhead microbiome therapeutics. In 2017, the company merged with Crestovo, thereby creating a leading platform in microbiome therapeutics. This consolidation bolstered their capacity to conduct advanced research and develop breakthrough treatments. Through the years, Finch has focused on developing a dynamic range of therapeutic microbiome products, establishing itself as an innovator in the field.
Products by Finch Therapeutics
Finch Therapeutics has multiple products in its pipeline targeting various therapeutic areas. The CP101, an investigational, orally administered microbiome candidate, has shown positive clinical data from Phase 2 trials for recurrent C. difficile infection. Other pre-clinical assets include FIN-524 targeting ulcerative colitis, FIN-525 aimed at Crohn’s disease, and FIN-211 for autism spectrum disorder. These products are designed based on insights gleaned from human microbiota transplantation studies.
Finch Therapeutics' Intellectual Property
Finch Therapeutics boasts a robust intellectual property estate with over 70 issued U.S. and foreign patents, alongside more than 140 pending patent applications. This portfolio includes foundational patents in the microbiome field with priority dates that precede the industry, providing extensive protection for composition of matter, methods of use, manufacture, and formulation claims into 2031. The IP estate delivers coverage for CP101 until 2036, ensuring a secure foothold in the microbiome therapeutics market.
Financial and Business Updates
Finch Therapeutics shared its first quarter 2023 financial results and provided business updates on May 10, 2023. Significant recent developments include the decision to discontinue the Phase 3 trial of CP101 for recurrent C. difficile in January 2023. The company decided to shift focus towards capitalizing on its IP estate and other assets. Moreover, Finch announced a reverse stock split of common stock on June 9, 2023, marking a strategic step in its business management.